| Bioactivity | Pegdinetanib (BMS-844203; CT-322) is a selective VEGFR-2 (VEGFR) inhibitor with Kds of 11 nM and 250 nM and IC50s of 16 nM and 240 nM for human and murine VEGFR-2, respectively. Pegdinetanib does not bind to VEGFR-1 or VEGFR-3. Pegdinetanib has antitumor activity[1]. |
| Invitro | Pegdinetanib（CT-322；55 nM；72 小时）抑制 VEGF-A 诱导的 HUVEC 增殖[1]。Pegdinetanib (CT-322; 0.36-24 nM) 阻断人脐带血管内皮细胞中 VEGF 诱导的 VEGFR-2 磷酸化和丝裂原活化蛋白激酶[1]。 Western Blot Analysis[1] Cell Line: |
| In Vivo | Pegdinetanib（CT-322；3-30 mg/kg；腹腔注射；每隔一天；持续 20 天）显着抑制裸鼠中已建立的 U87 人胶质母细胞瘤异种移植物的生长[1]。 Animal Model: |
| Name | Pegdinetanib |
| CAS | 906450-24-6 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Roni Mamluk, et al. Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2. MAbs. 2010 Mar-Apr;2(2):199-208. |